Literature DB >> 24512549

Diuron-induced rat urinary bladder carcinogenesis: mode of action and human relevance evaluations using the International Programme on Chemical Safety framework.

Mitscheli Sanches Da Rocha1, Lora L Arnold, Maria Luiza Cotrim Sartor De Oliveira, Shadia M Ihlaseh Catalano, Ana Paula Ferragut Cardoso, Merielen G N Pontes, Bianca Ferrucio, Puttappa R Dodmane, Samuel M Cohen, João Lauro V De Camargo.   

Abstract

Diuron, a high volume substituted urea herbicide, induced high incidences of urinary bladder carcinomas and low incidences of kidney pelvis papillomas and carcinomas in rats exposed to high doses (2500 ppm) in a 2-year bioassay. Diuron is registered for both occupational and residential uses and is used worldwide for more than 30 different crops. The proposed rat urothelial mode of action (MOA) for this herbicide consists of metabolic activation to metabolites that are excreted and concentrated in the urine, leading to cytotoxicity, urothelial cell necrosis and exfoliation, regenerative hyperplasia, and eventually tumors. We show evidence for this MOA for diuron using the International Programme on Chemical Safety (IPCS) conceptual framework for evaluating an MOA for chemical carcinogens, and the United States Environmental Protection Agency (USEPA) and IPCS framework for assessing human relevance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24512549     DOI: 10.3109/10408444.2013.877870

Source DB:  PubMed          Journal:  Crit Rev Toxicol        ISSN: 1040-8444            Impact factor:   5.635


  2 in total

1.  Screening for human urinary bladder carcinogens: two-year bioassay is unnecessary.

Authors:  Samuel M Cohen
Journal:  Toxicol Res (Camb)       Date:  2018-01-23       Impact factor: 3.524

2.  Diuron exposure and Akt overexpression promote glioma formation through DNA hypomethylation.

Authors:  Joséphine Briand; Arulraj Nadaradjane; Gwenola Bougras-Cartron; Christophe Olivier; François M Vallette; Pierre-François Cartron
Journal:  Clin Epigenetics       Date:  2019-11-14       Impact factor: 6.551

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.